This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to tavapadon prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-28; most recent amendment 2026-02-06.